Abstract
A cost analysis of the Port Delivery System (PDS) versus monthly intravitreal ranibizumab (IVR) in the treatment of neovascular age-related macular degeneration (AMD) was performed based on the 96-week ARCHWAY trial results.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
